Amlodipine Besylate is a calcium channel blocker (dihydropyridine) indicated for hypertension, chronic stable angina and vasospastic angina. We supply it to US manufacturers of tablets, oral suspension and fixed-dose combinations.
Data from PubChem (CID 60496) and FDA’s substance registry
CAS number
111470-99-6
Molecular formula
C26H31ClN2O8S
Molecular weight
567.1g/mol
FDA UNII
IUPAC name
benzenesulfonic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
InChIKey
ZPBWCRDSRKPIDG-UHFFFAOYSA-N
- Appearance
- White crystalline powder.
- Solubility
- Slightly soluble in water and sparingly soluble in ethanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Sensitive to light, so packaging and storage conditions belong in the specification. Strengths are expressed as amlodipine base: about 6.9 mg of the besylate salt delivers 5 mg.
On the US market
- Reference product
- NorvascNDA 019787
- Approved ANDAs
- 19 with a marketed product
- Approved forms and strengths
- Tablet 2.5 mg, 5 mg, 10 mg
- Powder for oral solution 2.5 mg per bottle, 5 mg per bottle, 10 mg per bottle
- Oral solution 1 mg/mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com